insights_auto
Why is LSTA down 6.10%?
Dive Deeperchevron_right
LSTA:NASDAQ
Lisata Therapeutics, Inc.
$1.38
arrow_downward
-6.10%(-0.090) 1D
Oct 5, 12:04:55 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
$1.45
High
$1.48
Low
$1.37
Mkt. cap
14.91M
Avg. vol.
502.82K
Volume
34.00K
52-wk high
$5.06
52-wk low
$0.99
EPS
-$1.64
Beta
0.94
Shares outstanding
9.01M
No. of employees
21
Open
$1.45
High
$1.48
Low
$1.37
Mkt. cap
14.91M
Avg. vol.
502.82K
Volume
34.00K
52-wk high
$5.06
52-wk low
$0.99
EPS
-$1.64
Beta
0.94
Shares outstanding
9.01M
No. of employees
21
News stories
From web sources and news partners
Investing.com Canada
·
4 hours ago
Marea Therapeutics doses first patient in MAR002 phase 2 trial By Investing.com
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, New Jersey, United States
SectorBiotechnology
Websitelisata.com